伤害感受素/孤啡肽FQ受体配体与转化挑战:聚焦西博帕多的创新镇痛
本文综述了N/OFQ受体(NOP)作为镇痛靶点的转化研究,重点介绍了混合阿片/NOP激动剂西博帕多。动物模型中,西博帕多对神经病理性疼痛疗效优于伤害性疼痛,呼吸抑制证据少,耐受性发展较吗啡慢。早期临床试验显示其对糖尿病神经病变、癌痛和腰痛有显著疗效。
要点
- NOP受体与μ受体共激活可在不损害镇痛的前提下减少副作用。
- 西博帕多在动物模型中呼吸抑制证据少,耐受性较吗啡发展慢。
- 早期临床试验显示西博帕多对糖尿病神经病变、癌痛和腰痛有显著疗效。
核心结论
- 西博帕多作为混合阿片/NOP激动剂,在动物模型和早期临床试验中显示出创新镇痛潜力。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 西博帕多在动物模型中对神经病理性疼痛的疗效优于伤害性疼痛。
- 动物模型中呼吸抑制证据少,与吗啡相比耐受性仅长期治疗后才出现。
- 早期临床试验显示西博帕多在糖尿病神经病变、癌痛和腰痛中疗效显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Opioids are characterised as classical (mu, delta, and kappa) along with the non-classical nociceptin/orphanin FQ (N/OFQ) receptor or NOP. Targeting NOP has therapeutic indications in control of the cardiovascular and respiratory systems and micturition, and a profile as an antidepressant. For all of these indications, there are translational human data. Opioids such as morphine and fentanyl (activating the mu receptor) are the mainstay of pain treatment in the perioperative period, despite a challenging side-effect profile. Opioids in general have poor efficacy in neuropathic pain. Moreover, longer term use is associated with tolerance. There is good evidence interactions between opioid receptors, and receptor co-activation can reduce side-effects without compromising analgesia; this is particularly true for mu and NOP co-activation. Recent pharmaceutical development has produced a mixed opioid/NOP agonist, cebranopadol. This new chemical entity is effective in animal models of nociceptive and neuropathic pain with greater efficacy in the latter. In animal models, there is little evidence for respiratory depression, and tolerance (compared with morphine) only develops after long treatment periods. There is now early phase clinical development in diabetic neuropathy, cancer pain, and low back pain where cebranopadol displays significant efficacy. In 1996, N/OFQ was formally identified with an innovative analgesic profile. Approximately 20 yr later, cebranopadol as a clinical ligand is advancing through the human trials process.
引用
- Calo G, Lambert DG. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic. Br J Anaesth. 2018. PMID: 30336855. doi:10.1016/j.bja.2018.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。